Ojjaara (momelotinib) is the only approved treatment for newly diagnosed and previously treated myelofibrosis patients[i] who have moderate to severe anemia and other key manifestations associated with the disease.[ii] This approval underscores… Read More
One of three patients in Cohort 5 achieved complete histological remission at 12 weeks. Consistent improvement in patient-reported outcomes with six of six evaluable patients in the fourth and fifth… Read More
mRNA therapies to be manufactured in Poland for developers of drugs to treat COVID, potential forms of cancer, and more The Historian automation system enables data integrity and compliance, setting… Read More
Sanofi and Existing Investor, Perceptive Advisors’ PXV Fund I, Invested a combined US$20 million as part of the Financing Sanofi to Receive Exclusive Right of First Negotiation Proceeds to Fund… Read More
EMPOWER-1 and EMPOWER-2 Phase 2 clinical trials did not meet their primary endpoint Emraclidine was well-tolerated with an adverse event profile consistent with Phase 1b trial NORTH CHICAGO, ILL – AbbVie (NYSE:… Read More
